TRIPLE NEGATIVE BREAST CANCER (TNBC) GLOBAL CLINICAL TRIAL LANDSCAPE (2024)

ESTIMATED

TNBC CASES

#DYK Did you know?



TNBC is a highly aggressive and heterogeneous subtype,



In the Asia-Pacific region, **China** reported an estimated higher incidence of TNBC cases

In Europe, **Germany** reported an estimated higher incidence of TNBC

The **United States** had the highest estimated number of TNBC cases in North America

In ROW, **Brazil** reported the highest incidence of TNBC



Marketed drugs such as **Immune checkpoint inhibitors** (e.g., Keytruda) and antibody-drug conjugates (e.g., Trodelvy) are vital in targeting TNBC pathways



Phase III trials focus on innovative **ADCs (e.g., datopotamab deruxtecan) and immune therapies (e.g., adagloxad simolenin)**, driving progress in TNBC treatment

comprising 10-15% of global breast cancer cases

Triple Negative Breast Cancer TRIAL CONTRIBUTIONS

The **Asia-Pacific** region shows **faster recruitment rates** than the United States

55% NORTH AMERICA & EUROPE



40%

The content of this publication is proprietary to Novotech Health Holdings. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses. Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech. Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights. For permissions or inquiries, please contact: communications@novotech-cro.com